Ilyang PharmaceuticalLtd Past Earnings Performance

Past criteria checks 2/6

Ilyang PharmaceuticalLtd's earnings have been declining at an average annual rate of -15.9%, while the Pharmaceuticals industry saw earnings growing at 4.4% annually. Revenues have been declining at an average rate of 7.1% per year. Ilyang PharmaceuticalLtd's return on equity is 4.3%, and it has net margins of 3.6%.

Key information

-15.86%

Earnings growth rate

-15.73%

EPS growth rate

Pharmaceuticals Industry Growth	11.32%
Revenue growth rate	-7.09%
Return on equity	4.35%
Net Margin	3.63%
Last Earnings Update	31 Dec 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Ilyang PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A007575 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 24	268,861	9,768	72,660	24,740
30 Sep 24	260,694	-596	71,724	25,924
30 Jun 24	262,184	783	70,718	23,297
31 Mar 24	264,839	-3,216	74,387	24,267
31 Dec 23	266,669	-2,365	73,211	23,748
30 Sep 23	231,394	5,653	66,214	24,541
30 Jun 23	244,616	8,582	68,109	24,886
31 Mar 23	242,399	15,826	65,897	23,226
31 Dec 22	247,773	18,936	68,641	22,395
30 Sep 22	260,618	20,909	76,233	21,369
30 Jun 22	247,702	20,882	72,959	19,035
31 Mar 22	246,121	19,658	70,516	18,643
31 Dec 21	242,511	14,032	70,212	16,829
30 Sep 21	351,562	11,559	135,128	18,647
30 Jun 21	353,265	8,727	130,360	18,822
31 Mar 21	353,771	8,045	130,575	18,719
31 Dec 20	343,329	10,880	124,820	19,723
30 Sep 20	336,954	10,558	123,825	19,832
30 Jun 20	324,142	9,487	125,151	18,064
31 Mar 20	319,242	8,493	123,360	18,555
31 Dec 19	324,573	9,985	127,632	15,850
30 Sep 19	323,111	703	127,264	14,046
30 Jun 19	311,322	-5,138	125,178	15,086
31 Mar 19	304,435	-4,821	123,568	12,168
31 Dec 18	300,036	-4,893	121,682	12,844
30 Sep 18	289,460	6,970	113,271	15,045
30 Jun 18	291,974	8,474	109,429	13,408
31 Mar 18	282,462	9,139	103,595	12,889
31 Dec 17	269,811	6,265	97,244	12,387
30 Sep 17	262,214	4,475	97,153	11,098
30 Jun 17	262,323	6,101	93,628	10,686
31 Mar 17	263,159	5,206	90,957	10,937
31 Dec 16	261,615	5,848	87,969	10,806
31 Dec 15	239,263	4,409	75,694	14,390
30 Sep 15	237,556	-2,266	78,189	8,671
30 Jun 15	226,844	-4,442	77,475	8,850
31 Mar 15	211,798	-10,962	76,060	8,361
31 Dec 14	195,872	-9,193	67,842	10,669
30 Sep 14	179,412	-5,320	59,085	10,972
30 Jun 14	158,829	-530	52,147	8,832

Quality Earnings: A007575 has high quality earnings.

Growing Profit Margin: A007575 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A007575's earnings have declined by 15.9% per year over the past 5 years.

Accelerating Growth: A007575 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A007575 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.06%).

Return on Equity

High ROE: A007575's Return on Equity (4.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 01:11
End of Day Share Price	2025/05/16 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ilyang Pharmaceutical Co.,Ltd is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Hyung Soo Kim	Cape Investment & Securities Co., Ltd.
Jae Hoon Shin	LS Securities Co., Ltd.
Jaechul Park	Mirae Asset Securities Co., Ltd. (Pre-Merger)